Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Galderma Company Rpofile"

07:30 EDT 31st July 2014 | BioPortfolio

Original Source: Galderma Laboratories

Galderma’s ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meeting the needs of dermatology patients and physicians. A fully-integrated specialty pharmaceutical company, Galderma was founded in 1981 and has over 3200 employees in 31 affiliates around the world. With approximately 20% of sales invested each year to discover and develop new products and access innovative technologies, Galder...

Matching Channels

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

Matching News

Nestle Increases Health Care Investment With Galderma Control

Galderma will be the “foundation” of a new division to be called Nestle Skin Health SA, said Nestle Chairman Peter Brake-Letmathe. L’Oreal will give Nestle its 50% stake in Galderma and $4.6 bil...

Nestle Buying Out Galderma from L'Oreal

GENEVA (AP) — Swiss food and drink giant Nestlé and French cosmetics company L'Oréal have approved a deal to transfer ownership of Swiss dermatology pharmaceuticals company Galderma. The companies...

Ipsen, Galderma Expand Neurotoxin Partnership

Ipsen, a global specialty-driven pharmaceutical company, and Galderma, a global healthcare company focused on dermatology and skin health, announced that they have significantly expa

Galderma finalizes major expansion in aesthetic and corrective dermatology in US, Canada

Galderma announced that it has gained full rights to distribute Restylane, Perlane, Emervel, Sculptra and Dysport from Valeant Pharmaceuticals International.

Ipsen and Galderma expand neurotoxins partnership

French drugmaker Ipsen and global dermatology and skin health company Galderma have expanded the scope of their neurotoxin partnership.

FDA Grants Orphan Drug Designation for Galderma’s Trifarotene Molecule in the Treatment of Congenital Ichthyosis

Galderma announced that the FDA granted Orphan Drug Designation status for the company’s trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to im...

Nestlé-Tochter Galderma baut Kooperation mit Ipsen bei Neurotoxinen aus

Zürich (awp) - Galderma, die vor kurzem vollständig von Nestlé übernommen wurde, und der französische Pharmakonzern Ipsen haben eine Vertiefung ihrer bereits bestehenden Zusammenarbeit im Bereich...

Ipsen, Galderma become exclusive partners for development and marketing of neurotoxins

Ipsen, a global specialty-driven pharmaceutical company, and Galderma, a global healthcare company focused on dermatology and skin health, has announced that they have significantly expanded the scope...

Matching PubMed Articles


Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement